Treatment of Adolescent Depression and Anxiety

Introduction to SNRIs

The American Academy of Child and Adolescent Psychiatry recommends switching to an SNRI, specifically venlafaxine extended-release, as the next step after SSRI failure in adolescents with depression and anxiety, with high-quality data supporting their use in this age group 1, 2
Venlafaxine extended-release has demonstrated efficacy in treating anxiety disorders in adolescents aged 6-17 years, with moderate to high strength of evidence for improving primary anxiety symptoms 1, 2
The American Academy of Child and Adolescent Psychiatry suggests that duloxetine is another viable option for generalized anxiety disorder in children and adolescents aged 7 years and older, although venlafaxine has more extensive data in the adolescent anxiety population 2

The American Academy of Child and Adolescent Psychiatry recommends regular monitoring of blood pressure and pulse due to the association of SNRIs, particularly venlafaxine, with sustained clinical hypertension and increased heart rate 2
Baseline blood pressure and pulse should be obtained before starting treatment, then monitored at each dose increase and regularly during maintenance, with common side effects including diaphoresis, dry mouth, nausea, decreased appetite, and insomnia 2
Venlafaxine carries a boxed warning for suicidal thinking and behavior through age 24, requiring close monitoring especially in the first months and after dose adjustments, with a higher suicide risk than other SNRIs and significant discontinuation symptoms 2, 3

The American Academy of Child and Adolescent Psychiatry recommends starting with venlafaxine extended-release 37.5-75 mg once daily, with increases by 37.5-75 mg increments every 4-7 days as tolerated, targeting 75-225 mg/day 1, 2
Full therapeutic benefit requires 8-12 weeks at therapeutic doses before concluding treatment failure, with adequate time allowed for response 1, 2

The American Academy of Child and Adolescent Psychiatry suggests that combining an SSRI with cognitive behavioral therapy (CBT) provides superior outcomes compared to either treatment alone and should be strongly considered before abandoning SSRIs entirely, with individual CBT prioritized over group therapy due to superior clinical and cost-effectiveness 1, 4
The Child-Adolescent Anxiety Multimodal Study demonstrated that combination treatment (CBT + sertraline) was superior to either monotherapy for anxiety disorders in youth aged 7-17 years, with moderate strength of evidence 1

The American Academy of Child and Adolescent Psychiatry recommends using caution with drugs that increase bleeding risk (aspirin, NSAIDs, warfarin) as SNRIs can cause abnormal bleeding, and monitoring for serotonin syndrome if combining with other serotonergic agents (triptans, tramadol, other antidepressants) 2

The American Academy of Child and Adolescent Psychiatry recommends never stopping venlafaxine abruptly, with gradual dose reduction mandatory to avoid discontinuation syndrome, and reducing dose by 37.5-75 mg every 4-7 days when discontinuing 2